Track topics on Twitter Track topics that are important to you
Takeda TiGenix Announce Publication Lancet Week Results Phase PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Takeda TiGenix Announce Publication Lancet Week Results Phase articles that have been published worldwide.
We have published hundreds of Takeda TiGenix Announce Publication Lancet Week Results Phase news stories on BioPortfolio along with dozens of Takeda TiGenix Announce Publication Lancet Week Results Phase Clinical Trials and PubMed Articles about Takeda TiGenix Announce Publication Lancet Week Results Phase for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Takeda TiGenix Announce Publication Lancet Week Results Phase Companies in our database. You can also find out about relevant Takeda TiGenix Announce Publication Lancet Week Results Phase Drugs and Medications on this site too.
Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved overall survival and progression-free survival compared with placebo in a randomised phase 2 study in patients with high MET expression (MET-high) hepatocellular carcinoma previously treated with sorafenib. The aim of this phase 3 study was to confirm the results of the phase 2 trial.
This phase III clinical trial compared the immunogenicity and safety of a purified chick-embryo cell rabies vaccine (PCECV) administered according to a shortened post-exposure prophylaxis (PEP) 4-site/1-week intradermal regimen, compared with the currently recommended 2-site/Thai Red Cross (TRC).
In this paper, we use the irradiance transport equation and the Fourier transform-based experimental solution given by Ichikawa-Lohmann-Takeda. We analyze experimental factors such as the digital filter, the introduced error for the rotation and period of the Ronchi ruling, and a new method is demonstrated for the measurement of 3D wavefront information.
Risankizumab, an anti-interleukin 23 antibody, was superior to placebo in achieving clinical and endoscopic remission at week 12 in a randomised, phase 2 induction study in patients with moderately to severely active Crohn's disease. Here we aimed to assess the efficacy and safety of extended intravenous induction and subcutaneous maintenance therapy with risankizumab.
We previously reported the 5-year results of the phase 3 IBCSG 23-01 trial comparing disease-free survival in patients with breast cancer with one or more micrometastatic (≤2 mm) sentinel nodes randomly assigned to either axillary dissection or no axillary dissection. The results showed no difference in disease-free survival between the groups and showed non-inferiority of no axillary dissection relative to axillary dissection. The current analysis presents the results of the study after a median follow-u...
Raltegravir 1200 mg once daily vs 400 mg twice daily, with emtricitabine and tenofovir disoproxil fumarate, for previously untreated HIV-1 infection: Week 96 results from ONCEMRK, a randomized, double-blind, non-inferiority trial.
Raltegravir 1200mg (2x600mg tablets) once daily (QD) demonstrated non-inferior efficacy and similar safety to raltegravir 400mg BID at Week 48 of the ONCEMRK trial. Here we report the Week 96 results from this study.
A strategy of immobilizing lead in the framework of ferrite-ceramic matrix, to reduce its environmental hazard was explored in this study. The mechanisms of incorporating lead into lead ferrites (δ-phase (2PbO·FeO), γ-phase (PbO·(2-2.5)FeO) and β-phase (PbO·(5-6)FeO)) was revealed by observing the phase transformation in the products. The δ-phase was dominantly formed at low temperature of 700-800 °C at Pb/Fe of 1/1-1/3. The significant growth of γ-phase was observed at 750-850 °C and Pb/Fe of...
Neutralizing interleukin (IL)-17F in addition to IL-17A may provide a more complete and specific approach to inhibiting inflammation.
Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen, Millennium Pharmaceuticals, and Onyx Pharmaceuticals; and is a member of advisory boards for Amgen, Bristol-Myers Squibb, Celgene Corporation, Incyte, Kite, Legend Biotech, Sanofi-Aventis, and Takeda Pharmaceuticals.
Methylphenidate (MP) is a commonly prescribed psychostimulant for Attention Deficit Hyperactivity Disorder (ADHD). We recently reported behavioral and developmental effects of chronic MP use in healthy rats. The current study investigated how interrupting chronic MP treatment with weekend abstinence altered the behavioral and physiological consequences of chronic MP treatment, and if prolonged abstinence would reverse the observed effects. Male Sprague Dawley rats were assigned to one of three treatment gro...
Comfort, P, Dos'Santos, T, Thomas, C, McMahon, JJ, and Suchomel, TJ. An investigation into the effects of excluding the catch phase of the power clean on force-time characteristics during isometric and dynamic tasks: an intervention study. J Strength Cond Res XX(X): 000-000, 2018-The aims of this study were to compare the effects of the exclusion or inclusion of the catch phase during power clean (PC) derivatives on force-time characteristics during isometric and dynamic tasks, after two 4-week mesocycles o...
We report results from a prospective phase I/II trial for patients with centrally-located, early-stage non-small cell lung cancer (NSCLC) receiving stereotactic body radiation therapy (SBRT).
A randomized, multicentre phase III study of three different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
Patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) show varying degrees of response to intravenous immunoglobulin (IVIg) therapy. This randomised phase III study in patients with CIDP (ProCID trial) will compare the efficacy and safety of three different doses (0.5, 1.0 and 2.0 g/kg) of IVIg 10% (panzyga®) administered every 3 weeks for 24 weeks. The primary efficacy endpoint is the rate of treatment response, defined as a decrease in adjusted Inflammatory Neuropathy Cause and T...
Nunes, RFH, Cidral-Filho, FJ, Flores, LJF, Nakamura, FY, Rodriguez, HFM, Bobinski, F, De Sousa, A, Petronilho, F, Danielski, LG, Martins, MM, Martins, DF, and Guglielmo, LGA. Effects of far-infrared emitting ceramic materials on recovery during 2-week preseason of elite futsal players. J Strength Cond Res XX(X): 000-000, 2018-We investigated the effects of far-infrared emitting ceramic materials (cFIR) during overnight sleep on neuromuscular, biochemical and perceptual markers in futsal players. Twenty athl...
Secukinumab is a recombinant monoclonal antibody that prevents interleukin 17A (IL-17A) from binding to its receptor, thus limiting inflammatory processes ultimately leading to excessive keratinocyte proliferation. According to phase-III clinical trials, it significantly reduces disease severity within a short period of time (PASI75>80% at week 12). Three real-life studies (47, 69 & 83 patients each) showed that 72.30%, 52.90% & 80.00% of treated subjects respectively achieved PASI75 at week 12. Still, more...
The goal of this work is to develop a simple microfluidic approach to characterizing liquid-liquid phase behavior in complex aqueous mixtures of organics and salts. We take advantage of the permeability of inexpensive microfluidic devices to concentrate aqueous solutions on chip. We demonstrate a technique that allows phase boundaries to be identified with high compositional resolution and small sample volumes. Droplets of single phase samples are produced on-chip and concentrated in the device beyond the p...